Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) EBITDA (2016 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed EBITDA for 10 consecutive years, with -$44.0 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 29.88% to -$44.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$231.7 million through Dec 2025, up 15.17% year-over-year, with the annual reading at -$231.7 million for FY2025, 15.17% up from the prior year.
  • EBITDA hit -$44.0 million in Q4 2025 for Rocket Pharmaceuticals, up from -$52.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$34.0 million in Q2 2021 to a low of -$73.7 million in Q2 2024.
  • Historically, EBITDA has averaged -$57.8 million across 5 years, with a median of -$62.4 million in 2023.
  • Biggest five-year swings in EBITDA: plummeted 81.28% in 2021 and later grew 29.88% in 2025.
  • Year by year, EBITDA stood at -$44.3 million in 2021, then crashed by 55.83% to -$69.1 million in 2022, then increased by 8.4% to -$63.3 million in 2023, then rose by 0.92% to -$62.7 million in 2024, then increased by 29.88% to -$44.0 million in 2025.
  • Business Quant data shows EBITDA for RCKT at -$44.0 million in Q4 2025, -$52.2 million in Q3 2025, and -$71.1 million in Q2 2025.